Singular Genomics Systems Inc

NASDAQ:OMICUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine is comprised of chemistry, including chemical compounds, polymers, and enzymes. Its product pipeline comprises two products, which include the G4 Sequencing Platform (G4) and the PX system (the PX). The G4 platform is a benchtop genomic sequencer designed to produce fast and accurate results. The G4 is designed to target the NGS market for particular applications. The PX is its second product in development and is a multiomics platform designed to target the markets for single-cell, spatial analysis and proteomics. Its PX platform leverages its sequencing technology, applying it as an in-situ readout to look at ribonucleic acid (RNA) and proteins in single cells and tissues.

Contact Information

Headquarters

3010 SCIENCE PARK ROADSAN DIEGO, CA, United States 92121

Phone

858-333-7830

Fax

302-531-3150

Executives

Chairman of the Board, President, Chief Executive Officer, Founder

Andrew Spaventa

Founder, Chief Scientific Officer

Eli Glezer

Chief Financial Officer

Dalen Meeter

Senior Vice President - Human Resources

Vincent Brancaccio

Senior Vice President - Corporate Development and Strategy

Jorge Velarde